Maintenance treatment with antipsychotic drugs for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Komossa, Katja ^a   Depping, Anna Mareike ^a   Heres, Stephan ^a   Kissling, Werner ^a   Davis, John M ^b   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; NEUROLEPTIC AGENT; PLACEBO;

AGGRESSION; AKATHISIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSTONIA; EMPLOYMENT; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MOTOR DYSFUNCTION; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIDE EFFECT; SUICIDE; WEIGHT GAIN;

EID: 77950150959     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008016     Document Type: Review

References (34)

1. Almerie 2007 Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006329]
2. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
3. Baldessarini 1985 Baldessarini RJ. Chemotherapy in psychiatry: principles and practice. Cambridge Massachusetts: Harvard University Press, 1985.
4. Berger 2003 Berger M. Psychische erkrankungen. Klinik und therapie. 2nd Edition. München: Urban & Fischer, 2003.
5. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
6. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
7. Carpenter 1994 Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
8. Davis 1975 Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry 1975;132(12): 1237-45.
9. Davis 1989 Davis JM, Barter JT, Kane JM. Antipsychotic drugs. Comprehensive textbook of psychiatry. Williams and Wilkins, 1989.
10. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town, 2000.
11. Der-Simonian 1986 Der-Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
12. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
13. Duggan 2005 Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/ 14651858.CD001359.pub2]
14. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13: 629-34.
15. Elbourne 2002 Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
16. Gilbert 1995 Gilbert P, Harris MJ, McAdams LA, Bowers MB, Charney DS, Glazer WM. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry 1995;52: 173-88.
17. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999; 149:876-83.
18. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008.
19. Kane 1988 Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative study group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-96.
20. Kay 1986 Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
21. Klein 1969 Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins, 1969.
22. Leon 2006 Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59:1001-5.
23. Leucht 2005a Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79: 231-8.
24. Leucht 2005b Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
25. Leucht 2009 Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet 2009;373:31-41.
26. Leucht 2009a Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Schwarz S, Davis JM. A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166:152-63.
27. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
28. Marvaha 2004 Marwaha S, Johnson S. Schizophrenia and employment ? a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
29. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-12.
30. Srisurapanont 2004 Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: DOI: 10.1002/14651858.CD000967.pub2]
31. Stata 2002 Stata Corporation. Intercooled Stata 7.0 for Windows. Stata Corporation, 2002.
32. Tsuang 1978 Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-55.
33. Wahlbeck 1999 Wahlbeck K, Cheine M, Essali MA, Rezk E. Clozapine vs typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 2. [DOI: DOI: 10.1002/ 14651858.CD000059]
34. Xia 2007 Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo. 2007.